Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD By Ogkologos - November 7, 2025 139 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATHENA-MONO/GOG-3020/ENGOT-ov45 study Source RELATED ARTICLESMORE FROM AUTHOR Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib Screening Programme by Primary Colonoscopy or Two Rounds of Two-Stool FIT Detects More Lower-Stage CRCs than Usual Care MOST POPULAR The UK Government’s response to Javed Khan’s tobacco review: A small... April 11, 2023 Breast Cancer Surgery Choice May Affect Young Survivors’ Quality of Life September 30, 2021 What Is a Living Will and Why Should You Create One... May 11, 2023 Only a Quarter of Phase III Studies Demonstrated Improved QoL in... July 18, 2022 Load more HOT NEWS FDA Approves Tivozanib for Relapsed or Refractory Advanced Renal Cell Carcinoma FDA Approves Osimertinib with Platinum-Based Chemotherapy for EGFR-mutated Locally Advanced or... Studying Molecular Subtypes of Peritoneal Metastases in Gastric Cancer Teacher Reads To Students One Day After Having Brain Surgery
